AGN - Allergan plc

NYSE - Nasdaq Real Time Price. Currency in USD
185.16
+0.95 (+0.52%)
As of 12:47PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close184.21
Open184.17
Bid184.99 x 800
Ask185.03 x 800
Day's Range183.34 - 185.39
52 Week Range142.81 - 237.41
Volume620,291
Avg. Volume2,079,070
Market Cap62.851B
Beta1.25
PE Ratio (TTM)N/A
EPS (TTM)-6.30
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & Yield2.88 (1.71%)
Ex-Dividend Date2018-05-17
1y Target Est208.45
Trade prices are not sourced from all markets
  • A Closer Look at Allergan’s Business Segments in Q2 2018
    Market Realist2 hours ago

    A Closer Look at Allergan’s Business Segments in Q2 2018

    As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and it now reports its revenues in three business segments.

  • Considering Allergan’s Q2 2018 Revenue Trend
    Market Realist3 hours ago

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

  • A Look at Allergan’s Valuation on August 16
    Market Realist5 hours ago

    A Look at Allergan’s Valuation on August 16

    Allergan (AGN) is a leading specialty pharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biological products.

  • If I Had to Buy 1 Stock in August, It Would Be This One
    Motley Fool5 hours ago

    If I Had to Buy 1 Stock in August, It Would Be This One

    This healthcare company appears poised to turn a corner.

  • 10 Roughed-Up Stocks to Buy for a Recovery Rally
    Kiplingeryesterday

    10 Roughed-Up Stocks to Buy for a Recovery Rally

    A stock's price can fall for many reasons. The company may no longer be performing as it's expected to. The industry or sector could be temporarily out of fashion. Sometimes, a weak market simply pulls good stocks down with it. As long as the issue isn't fundamental (and long-term), you can still buy low and eventually sell high, even in a toppy market like today's. Today, we will look at 10 stocks with market caps between $10 billion and $200 billion that have fallen hard in the past year, but that some analysts think are poised for a bounce-back. These companies are in a variety of industries - everything from banking to pharmaceuticals to industrial products to consumer goods. Clearly, each of these stocks comes with some risk given the bearish drivers that have dragged them down by 20%, 30%, even 40%. But investors should be less concerned about why these stocks fell in the past, and more concerned about whether they realistically can rebound from here. None of these stocks need to reach their old highs for investors to neatly profit - the underlying companies just need to follow through on proposed ways to increase shareholder value. Here's a look at 10 battered stocks to buy for their recovery potential. SEE ALSO: 20 of the Best Stocks You Probably Haven't Heard Of

  • How Is Bausch Health’s Salix Pharmaceuticals Positioned?
    Market Realistyesterday

    How Is Bausch Health’s Salix Pharmaceuticals Positioned?

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.

  • A Financial Overview of Bausch Health Companies in August
    Market Realist2 days ago

    A Financial Overview of Bausch Health Companies in August

    In the first half of 2018, Bausch Health reported revenue of $4.1 billion compared to $4.3 billion in the same period last year. Bausch Health reported net income of -$873 million in the second quarter compared to -$38 million in the same period last year. In the first half of 2018, Bausch Health reported net income of -$3.45 billion compared to -$590 million in the same period last year.

  • 3 Stocks for Warren Buffett Fans
    Motley Fool2 days ago

    3 Stocks for Warren Buffett Fans

    If you like the Oracle's style, these stocks are for you.

  • How Analysts View Bausch Health Companies in August
    Market Realist2 days ago

    How Analysts View Bausch Health Companies in August

    After the first half of 2018, Bausch raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. In August, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and US WorldMeds announced the launch of Lucemyra 0.18 mg tablets in the US market. Right now, Lucemyra is the first and only non-opioid drug indicated for the mitigation of opioid withdrawal symptoms for facilitating rapid opioid discontinuation in adults.

  • Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
    Zacks3 days ago

    Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

  • Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
    Zacks3 days ago

    Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why

    Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.

  • The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

    The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

  • Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
    Zacks7 days ago

    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

  • Editas Prepares for the Commercialization of EDIT-101
    Motley Fool8 days ago

    Editas Prepares for the Commercialization of EDIT-101

    The genome-editing specialist just offered its latest update on the state of the business. Here's what investors need to know.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist9 days ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript
    Motley Fool9 days ago

    Editas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript

    EDIT earnings call for the period ending June 30, 2018.

  • PR Newswire9 days ago

    Allergan Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board of Directors as Part of Active Board Refreshment Process

    DUBLIN, Aug. 8, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that Michael E. Greenberg, PhD will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Dr. Greenberg is the Nathan Marsh Pusey Professor of Neurobiology at Harvard University and the Co-Lead of the Allen Discovery Center for Human Brain Evolution at Harvard Medical School.

  • Bausch Health Companies Stock Rose ~8% after Q2 Results
    Market Realist10 days ago

    Bausch Health Companies Stock Rose ~8% after Q2 Results

    Bausch Health Companies stock was trading at $24.39 today, an ~8.40% increase from yesterday’s close of $22.50. On August 6, Bausch Health stock closed at $22.50, which represents a ~106% increase from its 52-week low of $10.94 on November 2, 2017. After Q2 2018 financial results, Bausch Health Companies raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. Bausch Health anticipates net revenues for the fiscal year 2018 to be in the range of $8.15 billion and $8.35 billion. 

  • Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
    Zacks10 days ago

    Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

    Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.

  • PR Newswire11 days ago

    Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

    DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

  • GlobeNewswire11 days ago

    Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

    Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

  • Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down
    Zacks14 days ago

    Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

    Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.

  • Eli Lilly’s Q2 2018 Earnings: Elanco
    Market Realist14 days ago

    Eli Lilly’s Q2 2018 Earnings: Elanco

    Elanco is Eli Lilly & Co.’s (LLY) animal health business. Elanco reported revenues of $792.1 million in the second quarter, representing 1.0% YoY (year-over-year) growth from $784.8 million in the second quarter of 2017. The chart below shows Elanco’s revenues since the first quarter of 2017.

  • Reuters14 days ago

    Spain's Almirall bets on dermatology with $650 mln U.S. deal

    Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash. The deal will make dermatology into Almirall's main growth driver, increasing the business's net sales to nearly 45 percent of the group total from 34 percent, Almirall said. "This is a transformational deal for Almirall.